Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab (QL1604) in advanced solid tumors
NCT05649761Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2019
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iparomlimab in solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-limiting toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Status: unknown.
02
Drugs
iparomlimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05649761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649761.